Martek (MTK) Announces Settlement of Patent Dispute with Capsugel France

FREE Breaking News Alerts from StreetInsider.com!

More News related to MATK

Paulson's Paulson & Co Shows New Stakes In Alpha Natural (ANR), Family Dollar (FDO), HP (HP); Raises Transocean (RIG) and Liquidates Pfizer (PFE)
Paulson's Paulson & Co. Reduces Citi (C) Exposure; Keeps Gold Level; Likes Tech (STX)(RIG)ABX)(JPM)
S&P Announces Changes to SmallCap 600: GEOI for HAWK, PSEC for MATK (GEOI) (HAWK) (PSEC) (MATK)
Top 10 News Items 12/20-12/23: Jo-Ann Stores Becomes Next PE Target; Economic Data Points Mixed; Q3 GDP Revised to 2.6%
Canaccord Genuity Moves Rating on Martek Biosciences (MATK) to Tender; DSM Sees the Value Shareholders Don't

More News related to Corporate News

September 10, 2009 10:56 AM EDT

Martek Biosciences Corporation (Nasdaq: MATK) announced earlier it has resolved a patent dispute with Capsugel France. The resolution follows Martek's November 2008 action for infringement filed in the High Court of Strasbourg, France.

As a result of this settlement agreement between Martek and Capsugel France, Capsugel and all of its affiliates have agreed to purchase all of their algal DHA exclusively from Martek for the life of the patent in question. Additionally, Martek and Capsugel will develop a product containing Martek's algal DHA in Capsugel's proprietary Licaps(R) liquid-filled hard capsules.